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Abstract
RNA-seq is a powerful tool for comprehensive characterization of whole transcriptome at both gene and exon levels and
with a unique ability of identifying novel splicing variants. To date, RNA-seq analysis of HBV-related hepatocellular
carcinoma (HCC) has not been reported. In this study, we performed transcriptome analyses for 10 matched pairs of cancer
and non-cancerous tissues from HCC patients on Solexa/Illumina GAII platform. On average, about 21.6 million sequencing
reads and 10.6 million aligned reads were obtained for samples sequenced on each lane, which was able to identify .50%
of all the annotated genes for each sample. Furthermore, we identified 1,378 significantly differently expressed genes
(DEGs) and 24, 338 differentially expressed exons (DEEs). Comprehensive function analyses indicated that cell growth-
related, metabolism-related and immune-related pathways were most significantly enriched by DEGs, pointing to a complex
mechanism for HCC carcinogenesis. Positional gene enrichment analysis showed that DEGs were most significantly enriched
at chromosome 8q21.3–24.3. The most interesting findings were from the analysis at exon levels where we characterized
three major patterns of expression changes between gene and exon levels, implying a much complex landscape of
transcript-specific differential expressions in HCC. Finally, we identified a novel highly up-regulated exon-exon junction in
ATAD2 gene in HCC tissues. Overall, to our best knowledge, our study represents the most comprehensive characterization
of HBV-related HCC transcriptome including exon level expression changes and novel splicing variants, which illustrated the
power of RNA-seq and provided important clues for understanding the molecular mechanisms of HCC pathogenesis at
system-wide levels.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide with an annual incidence of about
600,000 cases, 55% of which are in China [1]. The 5-year overall
survival rate of individuals with HCC is relatively low, which has
barely been improved over the past two decades. A better
understanding of the molecular pathways that are active in HCC
using a more comprehensive approach would potentially provide
new strategies for clinical prevention and therapy.
Currently, several global approaches including array-based
comparative genomic hybridization (CGH) [2], expression profil-
ing based on DNA microarrays [3], proteomics based on 2D
electrophoresis (2DG) and/or mass spectrometry (MS) [4] have
been used to detect the changes at different molecular levels
(DNA, RNA, or protein) in HCC, such as chromosomal
imbalance and genetic instability, epigenetic alteration, gene
expression, and gene regulation and translation. In particular,
microarray-based gene profiling is the most commonly used
method for studies on HCC including comparative analysis of
cancer vs. non-cancerous samples [3], early stage vs. late stage [5],
good prognosis vs. poor prognosis [6], and HCC patients with
HBV vs. those with HCV infection [7]. However, array-based
expression profiling has several limitations including incapability
of detecting gene fusions and novel alternative splicing. Array
analysis is further complicated by inconsistencies largely caused by
differences in the platforms and compromised by its limited
sensitivity in detecting lowly expressed genes [8,9].
With the advance of the next-generation sequencing technol-
ogies, RNA-seq has become a useful tool in defining the
transcriptomes of cells with the advantage of analyzing expression
at exon levels as well as delineating novel splicing variants [10,11].
Early application of RNA-seq included expression profiling of
yeast [12], mouse brain, liver and skeletal muscle tissues [13],
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several advantages over other expression profiling technologies
including higher sensitivity, ability to detect splicing isoforms and
somatic mutations [11]. For cancer expression profiling, Berger
et al. [15] applied RNA-seq to expression profiling of melanoma.
They identified 11 novel melanoma gene fusions and 12 novel
read-through transcripts, providing an example of novel avenues
for target discovery in cancers. To date, the RNA-seq analysis of
HBV-related HCC has not been published. We therefore applied
RNA-seq technology to analyze 10 matched pairs of HCC tissues
and their adjacent non-cancerous tissues.
Methods
Ethics
This study was approved by the institutional review boards of
the Forth Military Medical University. Written informed consent
with a signature was obtained from each patient.
Patients and Tissue Specimens
A total of 80 paired fresh-frozen tissue samples (cancer and
matched adjacent non-cancerous tissue) were collected from
Chinese HBV-related HCC patients undergoing surgery during
the period of August 2009 to March 2010 in the Eastern
Hepatobiliary Surgery Hospital of Shanghai, China. Diagnosis of
all HCC cases was histologically confirmed by two independent
pathologists and all tumor tissues was assessed by HE staining and
only those with the percentage of tumor cells more than 90% and
without necrosis were used for the analysis. Among HCC cases, 10
paired samples were randomly selected for RNA-sequencing. All
these 10 patients were HBV positive. The clinical features of the
patients were listed in Table S1.
RNA preparation and sequencing
Total RNAs were extracted, according to the manufacturer’s
instruction, from about 60 mg of tissues for each of the 10 paired
samples using the mirVana
TM miRNA Isolation Kit (Ambion
Inc.), which is also suitable for total RNA extraction. The RNA
yields were quantified by NanoDrop ND1000 (Thermo- Fisher
Scientific, Waltham, MA) and the RNA quality was assessed by
the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA). The
RNA integrity number (RIN) of every RNA sample used for
sequencing was more than 8. The cDNA libraries for 10 paired
samples were constructed using mRNA-Seq Sample Prep Kit
based on the Illumina Inc.’s guide. In brief, polyA-containing
mRNA was purified using oligo-dT beads from 10 ug of total
RNAs for each sample and fragmented into small fragments using
divalent cations under elevated temperature. The cleaved RNA
fragments were reverse-transcribed into first strand cDNA using
random primers (Invitrogen Inc.), followed by second-strand
cDNA synthesis. After end-repair processing, a single ‘A’ base was
added to cDNA fragments at 39 end. The cDNAs were then
ligated to adapters, purified by 2% agrose gel, and then enriched
by PCR to create the final cDNA library. Finally, RNA single-end
sequencing was performed using Solexa/Illumina Genome
Analyzer II using the standard protocol. The cDNA library of
each sample was loaded to a single lane of an Illumina flow cell.
The image deconvolution and calculation of quality value were
performed using Goat module (Firecrest v.1.4.0 and Bustard
v.1.4.0 programs) of Illumina pipeline v.1.4. For the 10 paired
samples, 8 pairs were sequenced using one lane, one pair using two
lanes and another pair using three lanes to assess the sequencing
depth. Sequenced reads were generated by base calling using the
Illumina standard pipeline. Each lane produced an average 20
million of 36-mer raw sequence reads.
Alignment of sequenced reads
All alignments were performed using a tool package SOAP2
[16], which was developed professionally for short oligonucleotide
analysis, allowing up to 2 mismatches with the references.
Sequenced reads were aligned to human transcript reference
sequences from the ENSEMBL database (Homo_sa-
piens.GRCh37.55.cdna.all.fa) for the expression analysis at
gene/transcript levels, and were aligned to genome sequence
and known exon-exon junction database from ENSEMBL for the
expression analysis at exon level. Reads that were unable to be
mapped to transcriptome were also aligned to novel exon-exon
junction database that was previously developed by our group for
detection of new alternative splicing events [17].
Evaluation of data quality and sequencing depth
To test the reproducibility of sequencing, the correlation of gene
expression between replicates of one sample was determined by
Pearson correlation coefficient (PCC). Similar analyses were also
performed to investigate the disparity of cancer and adjacent non-
cancerous tissues. To assess the effect of sequencing depth for
transcriptome analysis, we also determined the ability of increased
sequencing raw reads for the identification of additional genes
using a random sampling approach. Firstly, all raw reads of each
repeat sequencing runs were pooled together for samples A39C
and A39P. Then, 13 different bins of raw reads ranging from 5 to
65 million (using a step increase of 5 million) were randomly
selected from pooled A39C or A39P, which were sequenced using
three lanes in a flow cell. Each bin of random selected reads was
mapped to transcriptome and the number of matched genes was
tabulated for each bin and plotted.
Differential expression analysis of gene, exon and novel
exon-exon junction
After alignment to the transcriptome, the expression level of
genes was determined based on the value of RPKM (reads per
kilobase per million), which was calculated as the number of reads
mapped to the transcripts of one gene divided by the transcript
length and the number of total mapped reads in one sample [13].
For reads with multiple alignments, we arbitrarily assigned them to
the transcript with the highest expression levels (read counts) under
the assumption that the probability that the read is coming from
the more abundantly expressed gene is higher than from the less
abundant genes. For exon level expression analysis, reads were
aligned onto genome firstly, and then unaligned reads were
aligned onto the known exon-exon junction database from
ENSEMBL. The expression level of each exon or exon-exon
junction was also evaluated by RPKM, similarly calculated as the
number of reads mapped to unique exon divided by the exon
length and the number of total mapped reads in one sample. For
reads with multiple alignments, we assigned the reads to every
mapped exons if the read has #30 genome hits, while we
discarded them if the alignment hits more than 30 exons. The
number 30 was chosen to allow reads from gene families, of which
are quite big (e.g. olfactory receptor family), to be counted while
removing those highly abundant repeat sequence reads. For the
reads mapped to exon-exon junction, we added counts to each
junctional exon.
We performed principle component analysis of the RNA-seq
data using RPKM values of all genes for all samples. The first
principle component accounts for more than 86.5% of the
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clustering analysis for the expression of all genes revealed that our
HCC samples had no obvious heterogeneous classes or major
subtypes (data not shown). Therefore, paired difference tests
including the paired t-test and the paired wilcoxon signed rank test
were applied to estimate the significance of expression difference
based on RPKM value. In addition, edgeR [18], a recently
developed software package specifically designed for analyzing
RNA-seq data, was also used. A difference with P,0.05 for paired
t-test and paired wilcoxon signed rank test and FDR (false
discovery rate) ,0.05 for edgeR was considered as significant. To
assess the distribution of differentially expressed genes (DEGs) at
different expression abundance levels, MA-plot was made based
on the log2-transformed fold change (FC) of expression between
HCC and adjacent non-cancerous tissues and log2-transformed
average expression level for each gene across all samples.
Comparison between RNA-seq and public microarray
data
A public microarray dataset (GSE22058) was retrieved from the
GEO database. The reason why we chose this dataset is that it is
the most recent and the only large-scale dataset for the comparison
of 96 HBV-related HCC and 96 adjacent non-cancerous liver
tissues from Chinese patients [19], which are comparable to our
data derived from HBV-infected Chinese populations. The log2-
transformed average gene expression levels for common genes
(mapped by common refseq IDs) were used to calculate the PCC
values between the HCC tissues and the adjacent non-cancerous
tissues. The scatter diagram was also plotted to assess the dynamic
range of the gene expression level for both platforms.
Functional annotation and positional gene enrichment
analysis
The top 30 DEGs were analyzed with the gene annotation
database at NCBI and the PubMed literature for their relationship
with tumorigenesis. Additionally, three public databases of HCC,
OncoDB.HCC (http://oncodb.hcc.ibms.sinica.edu.tw), HCCnet
(http://www.megabionet.org/hcc/index.php), and EHCO (Ency-
clopedia of Hepatocellular Carcinoma genes Online, http://ehco.
iis.sinica.edu.tw) were used to assess the differential expression of
the DEGs in HCC-related datasets. Positional Gene Enrichment
[20] (PGE, http://homes.esat.kuleuven.be/,bioiuser/pge/), a
tool for the identification of over-represented chromosomal
regions in a given gene set., was used to survey the chromosomal
regions that are significantly enriched by differentially expressed
genes (DEGs). Statistical significance was evaluated by an FDR
value of ,0.001. The Ingenuity Pathways Analysis (IPA) software
package (Ingenuity Systems, www.ingenuity.com) was used to
identify enriched bio-function terms and canonical pathways using
gene symbols. Fisher’s exact test of P,0.05 was considered
significant. GSEA (Gene Set Enrichment Analysis) [21] was also
used to identify enriched gene sets. To investigate the relationship
of differential expressions at gene and exon levels, we plotted the
average read counts for each exon of 5,288 DEE-containing genes
in HCC tissues and adjacent non-cancerous tissues. Based on the
plots of read coverage, the exon expression pattern was empirically
classified.
Identification of novel differentially expressed exon-exon
junctions
We explored the possibility of RNA-seq in identifying novel
spliced transcripts consisting of novel splicing events of known
annotated exons. Several programs were available for such types
of analysis including QPALMA [22], Splicemap [23], Mapsplice
[24], TopHat [25], GSNAP [26] and PALMapper [27].
QPALMA used a machine learning algorithm to predict splice
junctions from a training set of positive controls [22]. SpliceMap
used flanking bases of splice site to locate potential splice sites [23],
but the Mapsplice algorithm detects splice junctions without any
dependence on splice site features [24]. The TopHat algorithm
pairs candidate exons and evaluates the alignment of reads to such
candidates [25]. GSNAP has the advantage of detecting both
short- and long-distance splicing, including interchromosomal
splicing [26]. PALMapper combines the read mapper Genome-
Mapper with the spliced aligner QPALMA [27]. In this study, we
took a similar approach to TopHat. However, instead of pairing
all potential exons, we only used exon-pairs that are compatible in
phases. A phase indicates the position within a codon where an
exon ends or starts [17]. Phase 0 indicates that an exon ends and
starts after a codon ends or starts; phase 1 indicates that an exon
ends and starts between the first and second base of a codon; and
phase 2 indicates that an exon ends and starts between the second
and third bases of a codon. Only combinations of exons that are in
phase would not create any frame-shift after translation. In
addition, in order to only identify those novel splicing events, we
built a putative novel exon-exon junctional databases excluding all
known exon-exon junctions annotated in all public domains
including NCBI and EC genes [17]. Aligning of sequenced reads
to this dataset would allow us to identify only novel splicing events
that were not previously reported in EST sequencing or annotated
in the public domains. Reads overlapping at least 8 base stretches
from either side of junctions were considered putative splicing
events. Furthermore, we restricted ourselves in identifying only
those differentially expressed novel splicing events. The expression
level of identified novel exon-exon junctions was evaluated by
TPM (Tag per million) value. The aforementioned statistical
methods were used to determine the expression difference of novel
exon-exon junctions between HCC tissues and adjacent non-
cancerous tissues.
Validation of differentially expressed genes, exons and
novel exon-exon junctions
Quantitative reverse transcription polymerase chain reaction
(qRT-PCR) was used for the validation of differentially expressed
genes, exons and novel exon-exon junctions. Seventy-six pairs of
samples including 6 used for sequencing were applied for
validation of DEG, while 20 pairs of samples were used for the
validation of differentially expressed exons and novel exon-exon
junctions. First, total RNA was extracted from tissue samples using
E.Z.N.A. Mag-Bind Total RNA Kit I (Omega Bio-Tek, USA)
following the protocol of manufacturer and then cDNA were
synthesized from the total RNA using PrimeScript RT reagent kit
(Takara, Japan). For the validation of DEGs, six genes were
randomly picked from top 100 DEG list. They are ANLN (Anillin,
actin binding protein), GTSE1 (G-2 and S-phase expressed 1),
KIF14 (Kinesin family member 14), MARCO (Macrophage
receptor with collagenous), PTIGS (prostaglandin I2 (prostacyclin)
synthase), and TFPI2 (Tissue factor pathway inhibitor 2). For the
validation of differently expressed exons, 3 representative genes
(CFTR of pattern 1, CCDC50 of pattern 2, SIGLEC11 of pattern 3)
were chosen to illustrate 3 relationship patterns between DEEs and
DEGs. The expression level of one pair of exons for each
representative gene was compared between HCC tissues and
adjacent non-cancerous tissues. The expression ratio for both
exons of the same representative gene was also determined in
HCC and adjacent non-cancerous tissues. For the validation of
differently expressed novel exon-exon junction, the candidate list
Transcriptomic Sequencing of HCC
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sequence overlaps at the novel exon-exon junctions. Six novel
exon-exon junctions with best read coverage and sequence
overlaps were selected, among which 4 were up-regulated and 2
were down-regulated in HCC tissues compared with adjacent
tissues. For the validation of DEGs, Taqman assay approach
(Premix Ex Taq
TM kit) (Takara, Japan) was used. For the
validation of DEEs, SYBR Green-based qRT-PCR approach
was used with the SYBR Premix Ex Taq
TM II kit (Takara, Japan).
MX3005P QPCR System (Stratagene, USA) was used for
quantitative RT-PCR according to the manufacturer’s instruc-
tions. The primers and probes for Taqman approach were
custom-designed and synthesized by Genecore Inc. (Shanghai,
China). The PCR primers for SYBR Green-based approach were
designed using Primer Premier 5.0 software (PREMIER Biosoft
International, Palo Alto, CA, USA) and synthesized by Invitrogen
Inc. (shanghai, China). The sequences of primers and probes, and
the conditions of qRT-PCR reactions were listed in Table S2. The
HPRT1 gene was used as internal control. The relative expression
level was determined using delta-delta CT method as previously
described [28].
Results
RNA-seq analysis of 10 matched pairs of HCC and
adjacent non-cancerous tissues
We performed RNA-seq on 10 pairs of matched HCC and
adjacent non-cancerous tissues from Chinese HCC patients using
the Illumina platform. The characteristics of the data were
summarized in Table 1. On average, about 21.6 million
sequencing reads and 10.6 million aligned reads were obtained
for samples sequenced on one lane. It was commonly reported in
the RNA-seq papers that a significant percentage of the sequence
reads could not be mapped to the transcribed database [29].
There are several reasons for this, including 1) SNPs or other types
of genetic variations; 2) repetitive elements and tandem repeats. 3)
novel isoforms, splicing events or novel transcripts. Additionally,
the transcript database that we used does not contain some RNA
species such as U6 RNAs, small nucleolar RNAs, long non-coding
RNA (lncRNAs) etc. Finally, there could be unspliced RNAs or
genomic DNA contaminations. The average numbers of mapped
genes, mapped transcripts or mapped exons were 24,356, 45,787
and 224,289, respectively. For each individual sample, we were
able to identify about 64% of all the annotated genes that are
expected to be almost equal to all detectable expressed genes in a
given tissue. In the ENSEMBL database, the human database
(Homo_sapiens.GRCh37.55.cdna.all.fa) includes 37,874 gene
entries (ENSEMBL genes) and 95,605 transcript entries (EN-
SEMBL transcripts). In total from the 10 pair samples, we
generated about 269 million (268,557,458) of aligned reads, which
to our knowledge is the largest database representing transcripts
expressed in HCC tissues. Combining all 10 paired samples, we
were able to identify 33,262 genes (87.8% of all ENSEMBL genes)
with one or more tags (Table S3). Furthermore, we calculated the
average number of sequence tags that a gene has for the 20
samples, and we found that 17017 genes (51.2% of all ENSEMBL
genes) have more than 10 mapped tags per kilobase (kb) of the
transcript length and 24,062 genes (63.5%) with more than 3
RPKM. For the transcripts, we were able to identify 81.87% of
(78,273 of 95,605, total entries in Homo-sapiens.GRCh37.55.cd-
na.all.fa) transcripts.
To assess the depth of sequencing coverage required for
transcriptome analysis, we re-sequenced one paired samples
(A13C and A13P) on two lanes and another paired samples
(A39C and A39P) on three lanes. Correlation analysis showed a
good reproducibility between replicates with all Pearson Correla-
tion coefficient (PCC) values.0.99 (Table S4). Our results
indicated that the number of mapped genes or exons for paired
samples (A39C and A39P) was not significantly increased for
sequenced samples on 2 or 3 sequencing lanes, compared with
those on one sequencing lane (Fig. 1A). In addition, because of the
random sampling nature of the next-generation sequencing
technology, we sought to use a random sampling approach to
determine how many millions of sequence reads were sufficient to
identify almost all genes expressed in a given tissue. The random
sampling process was done using the raw reads, not mapped reads.
We randomly sampled 5 to 65 million (using a step increment of 5
million) reads from the total raw reads that we have accumulated
for sample A39P or A39C, and found that about 15 million raw
reads were sufficient to identify more than 50% (21,170 genes,
56%, i.e. 21,170/37,874) of the annotated genes, which is almost
equal to all detectable expressed genes in a given human tissue
based on estimation from two large scale transcriptome studies
[30,31]. The gene coverage increased much slowly when the read
size was larger than 15 million (Fig. 1B), suggesting that using a
single sequencing lane (which can generate about 20 million raw











A05 1/1 20996588/22432079 10249035/12311804 25526/24104 46128/45190 237072/242629
A19 1/1 23586239/20834934 11485721/8843629 22127/22053 41210/39098 225402/205872
A31 1/1 23563690/21130309 11100731/10055694 25083/23924 47350/44033 250004/234018
A35 1/1 23060264/21127532 12602425/9179290 23447/22013 44553/38503 238811/195939
A57 1/1 21205625/20862092 10696149/13342966 23525/23676 43603/44300 237896/239578
A60 1/1 23315039/23481219 14396820/13525402 22706/23695 43207/44239 238530/241133
A63 1/1 20584096/20932296 11021167/8609693 21846/26041 41333/47528 226128/251622
A82 1/1 21068533/20378488 9967105/8401477 23354/25311 42401/45469 226371/220435
A13 2/2 39690126/40643375 13109377/18295444 29700/26164 57579/52158 267445/264099
A39 3/3 64805390/64921421 30429840/30933689 26891/25943 55220/52655 265052/256931
Notes: T/NT, tumor/non-tumor; Aligned reads were defined as those mapped to reference transcripts.
doi:10.1371/journal.pone.0026168.t001
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when considering cost and benefit.
RNA-seq data were comparable to the array data for
Chinese HCC
To assess the quality of RNA-seq data and see whether it has
advantages over array-based approaches, our RNA-seq data was
compared with the public microarray data (GSE22058). We
performed correlation analysis of log2-transformed average gene
expression level for common genes between the RNA-seq data and
the microarray data. We found that the PCC was 0.8557 and
0.8620 for the pooled HCC tissues and pooled adjacent non-
cancerous tissues, respectively, suggesting a high correlation
between the two platforms. This observation was consistent with
previous report that RNA-seq data is comparable to the array data
[9]. In addition, we found that RNA-seq data captured a much
wider dynamic range of expression level (tumor: 29.0737 to
14.2033; non-tumor: 210.4580 to15.6266) than array data
(tumor: 2.0721 to 14.7653; non-tumor: 2.0358 to 14.6850) in log
scales (Fig. 2A and 2B).
Identification of differential expression at gene levels
We identified a total of 1,378 significantly differently expressed
genes (DEGs) with 808 up-regulations and 570 down-regulations
in HCC, when compared with non-cancerous adjacent tissues
(Table S5). The numbers of DEGs seem to be evenly distributed at
different expression abundance levels (Fig. 3A). The top 30 DEGs,
which were identified based on descending ranking of FDR from
the edgeR program, were listed in Table S6. A more systematic
comparison of these 30 DEGs in 3 public HCC databases revealed
that 22 DEGs (73.3%) were identified to be DEGs in at least one
of the three databases. Validation analysis using quantitative RT-
PCR for randomly picked six DEGs demonstrated the consistent
over-expression for ANLN, GTSE1 and KIF14 and the consistent
under-expression for MARCO, PTGIS and TFPI2 in HCC (Fig. 3B).
Interestingly, we found that the average PCC (0.9083) for any two
adjacent non-cancerous tissues was significantly higher than that
(0.7218) for any two cancer tissues or that (0.7336) for any cancer
and non-cancerous tissue pairs, suggesting a higher degree of
biological heterogeneity in HCC tissues compared with non-
cancerous adjacent tissues (Fig. 4A.)
The chromosome regions enriched by DEGs were analyzed
using PGE software. Using a much stringent FDR value of
,0.001), up-regulated genes or down-regulated genes in tumor
tissues were significantly enriched at 18 or 9 chromosome regions
respectively. In 14 non-redundant enriched regions (4 of the 18 are
redundant) that were enriched by the up-regulated genes in HCC
(Table S7), eleven of them (about 73%) were reported to be
amplified in HCCs and four of them were not reported in the
literature. A similar literature searches identified 6 out of 9 regions
enriched by down-regulated genes in HCC tissues showed allele
loss or rearrangement that could explain the down-regulation of
genes. Three of the 9 regions did not have literature report of allele
losses (Table S8). The most significant enrichment was located at
chromosome 8q21.3–24.3 (90839173–141714827) with up-regu-
Figure 1. Assessment of sequencing depth required for transcriptome analysis. (A) Gene coverage of three sequential runs for sample
A39P and A39C. (B) Gene coverage for 13 different bin size of million reads randomly chosen from the total sequenced reads of sample A39P or A39C.
doi:10.1371/journal.pone.0026168.g001
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be further refined to chromosome 8q24.1 (120812196–
126448543) with up-regulation of 18 genes among 30 (Fig. 4B).
Additionally, we also found that 1q22–23 was significantly
enriched by over-expressed genes in HCC, with 9 of 37 genes in
this region up-regulated. A smaller region within 1q22–23
Figure 2. Correlation analysis of log2-transformed gene expression level between RNA-seq data and public microarray data
(GSE22058) in (A) pooled tumor tissues and (B) non-tumor tissues. Red line stands for the best fit line, and the black line stands for the 45
degree reference line.
doi:10.1371/journal.pone.0026168.g002
Figure 3. The distribution of differentially expressed genes in MA plot (A) and their validation by qRT-PCR (B). Fold change (T/NT) of
the expression level for a given gene was defined as the read counts of the gene in the tumor sample (T)/the read counts in the non-tumor sample
(NT); Concentration for a given gene was defined as the read counts of gene/the total read counts in HCC sample+the read counts of the gene/the
total read counts in non-cancerous samples. Each dot represents a gene. Yellow dots represent the genes with no counts in either HCC tumor or non-
cancerous tissues. Red dots represent the genes with significantly differential expression. Red rings represent those samples also used for RNA-seq
analysis.
doi:10.1371/journal.pone.0026168.g003
Transcriptomic Sequencing of HCC
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26168Figure 4. Functional annotation of DEG. (A) Analysis of homogeneity for HCC and adjacent non-cancerous tissues using PCC values. The PCC
values of gene expression between different samples were represented by different colors: bigger value corresponding to darker color. AVE: Average
raw reads number for each gene from re-sequenced sample. The character C represents cancerous tissue sample and P for peri-cancerous tissue
sample. (B) Enrichment regions of up-regulated genes on Chromosome 8. (C)Top 10 bio-function terms enriched by DEGs and (D) top 10 canonical
pathways enriched by DEGs. Percentage represents the ratio of the number of mapped genes to all genes in a pathway from IPA. Threshold was set
(P,0.05 or 2log (p).1.3) by Fisher’s Exact Test.
doi:10.1371/journal.pone.0026168.g004
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were also identified as chromosome aberrations in previously study
[32,33]. Furthermore, we found many novel potential chromo-
some aberrations including 15q15.1 that was enriched with up-
regulated genes, and 10q23 and 9q34 that were enriched with
down-regulated genes in tumors. These regions were not found in
previous array-CGH analysis of HCC [2].
Using the IPA software package, we identified 54 significant
bio-function terms and 41 significant canonical pathways (Fisher’s
Exact Test, P,0.05) (Table S9 and Table S10). The top 10
significant bio-function terms and canonical pathways were shown
in Fig. 4C and 4D, with cancer and G2/M DNA damage
checkpoint regulation in cell cycle ranking the highest. Most of
other bio-function terms and pathways were also closely related to
tumorigenesis, such as cell cycle, cell growth and proliferation,
lipid metabolism, DNA replication and repair.
Finally, we analyzed the DEGs using a tool GSEA and found
that the top enriched set is the targets of miR199A and B
(P=0.002) when using C3.all.v2.5 gene sets (C3 represents all
motif gene sets including microRNA targets and transcriptional
factor targets). The genes of BCAM (basal cell adhesion molecule),
NCOA2 (nuclear receptor coactivator 2) and NPAS2 (neuronal PAS
domain protein 2) were listed in this gene set that were up-
regulated in HCC tissues when compared with the adjacent non-
cancerous tissues. When C2.all.v.2.5 gene sets (C2 represents all
curated genes) were used, the top gene sets enriched by up-
regulated DEGs in cancer is the SMITH_LIVER_CANCER gene
set (P=0.0039), which contains potential marker genes specifically
up-regulated in the majority of HCV-related HCC [34]. Other
enriched gene sets with P value,0.05 were listed in Table S11.
Complex pattern of gene regulation revealed by RNA-seq
coupled with exon-level analysis
We analyzed differential expression at exon levels by mapping
sequenced reads to each individual exon of genes. Totally, about
85.66% of (329891/385122) all annotated exons in the human
genome were mapped when combining the 10 pairs of samples.
Using the same statistical analysis procedures aforementioned for
DEGs, we obtained a total of 24, 338 differentially expressed exons
(DEEs) between HCC and adjacent non-cancerous tissues (data
available when required), which correspond to 5288 genes. Among
these, 1274 of these genes were also identified by the gene level
analysis (1378 DEGs genes identified at gene levels). However,
4014 of these genes showing differential expression at the exon
levels were not found in the DEGs that were identified at the gene
levels, suggesting that RNA-seq data combined with exon level
analysis might capture a much more complex landscape of
differential gene expressions. A Venn diagram illustrating the
overlaps was shown in Fig. 5. Since the length of the tag sequence
we used for the alignment is 36 base pair, and we allowed up to
two mismatches (2/36, i.e. 5.56%), unless the HCC cancer
transcriptome has a mutation rate greater than 5.56%, there
would not be any bias of exon-level expression caused by the
sequence differences in the tumor and normal tissues. We have
checked the mutation rate of HCC and found that it is similar to
other types of cancers. We found that there are 743 to 3050 SNPs
per transcriptome among the 20 samples and there is no
significant difference in the number of SNPs between the HCC
and the adjacent tissue group (Data not shown). Assuming that we
covered about 2% of the genome (about 2% of the genome are
exons), then the polymorphism (including somatic mutation) rate
would be around 0.0012–0.0051%.
To gain detailed understanding of the differential expression at
exon levels and the relationship of differential expression analysis
between gene level and exon level, we plotted the read counts for
each exon of 5288 genes. Several patterns emerged. Representa-
tive expression patterns were illustrated in Fig. 6. The most
common pattern (pattern 1) (Fig. 6A) showed consistent differential
patterns for all exons of DEGs. These genes would be identified as
differentially expressed by either exon-level or gene-level analytical
approaches. A more interesting pattern is illustrated by pattern 2
(Fig. 6D) where selected exons were differentially expressed while
the rest of the exons were not differentially expressed. However,
the direction of expression changes (up or down regulation) is the
same for the differentially expressed exons (DEEs). Finally, there
are more complex patterns (pattern 3) (Fig. 6G) where both up-
and down-regulated DEEs exist for the same gene, suggesting a
complex regulation mechanism. We have retrieved mapped reads
from the exon-exon junction alignments for 3 exampled genes. We
did observe the sequence reads that mapped to the exon-exon
junctions and found different junction alignments for 3 exampled
genes in HCC and non-cancerous tissues. These results were in
consistence with corresponding DEEs and evidently support the
alternative splicing as the explanation for the exon expression
difference (data not shown).
We further confirmed the existence of all these patterns by
quantitative RT-PCR using 20 HCC patients (Fig. 6B, C, E, F, H,
I). CFTR (cystic fibrosis transmembrane conductance regulator)
represents pattern 1 of DEGs. We found that the two DEEs
(ENSE00000718634, ENSE00000718704) of this gene were both
significantly down-regulated to similar extent in tumor tissues
when compared to non-tumor tissues (both P,0.001) (Fig. 6B).
However, the ratio of these two DEEs showed no difference
(P=0.185) between tumor and non-tumor tissues (Fig. 6C). The
gene CCDC50 (coiled-coil domain containing 50) represents
pattern 2. One DEE (ENSE00001334610) of CCDC50 in pattern
2 was significantly down-regulated in tumor tissue (P,0.001),
while another DEE (ENSE00001552245) exhibited no significant
expression difference between tumor and non-tumor tissues
(P=0.9496) (Fig. 6E). The ratios of expression level of two exons
in CCDC50 were clearly higher in tumor tissues than that in non-
tumor tissues [median (range): 25.2775(27.045, 22.335) vs.
21.8725(23.175, 20.97) P,0.001] (Fig. 6F). Finally, the gene
SIGLEC11 (sialic acid binding Ig-like lectin 11) represents pattern
3. One DEE (ENSE00001756179) of SIGLEC11 was significantly
up-regulated in tumor tissue (P,0.001), while another DEE
Figure 5. Venn diagram of intersection between 1378 DEGs
and 5288 DEE-contained genes.
doi:10.1371/journal.pone.0026168.g005
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(Fig. 6H). The ratios of expression level of two DEEs in SIGLEC11
were considerably different between tumor and non-tumor tissues
[median (range): 0.8475(0.1, 2.875) vs. 21.3025(23.610, 20.185)
P,0.001] (Fig. 6I).
Identification of novel differently expressed splicing
variants
We explored the possibility of RNA-seq in identifying novel
spliced transcripts consisting of novel splicing events of known
annotated exons using a similar approach to TopHat. Finally, we
identified 61 differently expressed novel exon-exon junctions
between HCC and adjacent non-cancerous tissues in 29 genes
(Table S12). We selected six novel junctions for validation in 20
HCC patients using qRT-PCR and agrose gel electrophoresis.
However, we were only able to confirm one novel junction in
ATAD2 (ATPase family, AAA domain containing 2) gene in the
samples. Furthermore, the novel splicing variant of ATAD2 was
detected to be with significantly higher frequency and abundance
in HCC compared to adjacent non-cancerous tissues (in only 5
adjacent non-cancerous tissues but in all 20 HCC tissues,
p,0.001) (Fig. 7B). PCR confirmation analysis showed that the
novel splicing event was only found in tumor samples but not in
adjacent tissues (Fig. 7C).
Discussion
In this study, we conducted the comprehensive transcriptome
sequencing for 10 HCC and 10 non-cancerous adjacent liver
tissues (matched pairs). An analysis using repeated sequencing runs
and random sampling simulations showed that about 15 million
raw reads were sufficient to cover 50% (21,170) of all the
annotated genes. Jongeneel et al. [31] comprehensively analyzed
Figure 6. Analysis and validation of DEEs. (A), (D) and (G): Schematic diagrams of 3 representative genes (CFTR, CCDC50, SIGLEC11) illustrating 3
relationship patterns between DEEs and DEGs. The structure of genes, together with all annotated exons and transcripts, were shown at the bottom.
The DEEs were highlighted in red on annotated exons of transcripts showing at the bottom. Red curve represents the normalized read counts for
HCC tissues and blue curve represents the normalized read counts for adjacent non-cancerous tissues. (B), (E) and (H): Comparison of expression
levels of DEEs in three representative genes between HCC and adjacent non-cancerous tissues. (C), (F) and (I): Comparison of expression ratio for
different DEEs of the same representative gene in HCC and adjacent non-cancerous tissues. T: tumor NT: Non-tumor.
doi:10.1371/journal.pone.0026168.g006
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sequencing (MPSS) in human tissues and concluded that about
50% of genes in the human genome are expressed in a given
tissue. Sugarbaker et al. [35] showed that about 15000 genes could
be detected by one or more reads using about 2.5–3 millions reads
and they demonstrated that the slope of gene coverage reaches a
plateau after 5 million sequence reads. Since not all genes are
expressed at given tissues, our ability to sequence 17K genes at
sequence depth of .10 tags per gene was quite good. We believe
that this sequence depth allowed meaningful comparison of at least
51.2% of the genes. Therefore, our sequencing reads of .20
million for each sample should be sufficient for transcriptome
analysis considering cost and benefit. Furthermore, a comparison
between our RNA-seq data and the public microarray data
illustrated that deep sequencing could detect a much wider
dynamic range of gene expression than microarrays. Expression
profiling analysis by arrays is limited by its low sensitivity due to
background hybridization and sometimes reduced specificity due
to cross-hybridization of probes and targets [8,9]. RNA-seq is a
more sensitive technology and it is thus not surprising to see that
we identified additional novel DEGs. To the best of our
knowledge, this represents the most comprehensive characteriza-
tion of the transcriptome of liver tissues, which is critical to
understand the disease at system-wide levels as any missing data
will create biased view of the system.
We first analyzed the expression difference at gene levels
between HCC and matched non-cancerous adjacent tissues and
identified 1378 differentially expressed genes (DEGs), many of
which were identified as differentially expressed in previous studies
such as GPC3 (glypican 3) [36], TERT (telomerase reverse
transcriptase) [37], SPINK1 (serine peptidase inhibitor, Kazal type
1) [38] and ESM1(endothelial cell-specific molecule 1) [39]. Many
additional novel and un-annotated genes were identified, suggest-
ing the power and sensitivity of the RNA-seq based approach for
expression profiling. Functional analyses indicated that 1378
DEGs were mostly enriched in the 54 bio-function terms and 41
canonical pathways, which provided important clues for under-
standing the molecular mechanisms of HCC pathogenesis. Among
these pathways, most of them have been previously characterized
as onco-signal pathways in HCC pathogenesis like cell cycle
pathway, molecular signaling pathways of MAPK, p53, BRCA1,
although several pathways were only indicated previously on the
basis of very few mapped genes [3,40]. Actually, comparing to
previous reports, we have identified more mapped genes with
significant expression changes in several pathways (data not
shown). For example, more members of cyclin family and MAPK
(Mitogen-Activated Protein Kinase)-related family were found to
be up-regulated in HCC tissues compared with adjacent non-
cancerous tissues.
Figure 7. Analysis and confirmation of a differently expressed novel exon-exon junction identified for the ATAD2 gene. (A) A
schematic diagram of the differently expressed novel junction in ATAD2. Red line represents tumor tissues and blue line represents adjacent non-
cancerous tissues. The structure of gene was plotted at the bottom. The connecting lines below exons represent all known annotated junctions. The
red connecting line above exons represents the predicted novel exon-exon junction. (B) Relative expression of the novel junction of ATAD2 in HCC
and non-cancerous tissues. (C) RT-PCR analysis on agrose gel electrophoresis for the novel junction in HCC and non-cancerous tissues from 2 HCC
patients. HPRT1 was used as the internal control. (D) A schematic diagram of amino acid sequence for exon 6–8 in ATAD2 gene.
doi:10.1371/journal.pone.0026168.g007
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fundamental and conserved metabolism processes, such as
biosynthesis of steroids, retinol and fatty acid. Particular
interestingly is the observation that many members of cytochrome
P450 (CYP450) family were significantly down-regulated in HCC
tissues, which is consistent with reported data on reduced activities
and down-regulated expression of various P450 molecules in the
liver [41]. This is not surprising because liver cancer could cause
the loss of normal hepatic cells that produce P450 enzymes.
Another noteworthy finding was the down-regulation of many
immune-related genes in HCC tissues, such as heavy and light
chain genes of immunoglobulin and immunoglobulin receptor
genes. This could be caused by the fact that the tumor tissues
might have fewer lymphocytes than the adjacent non-cancerous
liver tissues as HCC often have lymphocyte infiltration [42].
Finally, we also found that the targets of miR199A and B were
enriched in the DEGs, including BCAM, NCOA2 and NPAS2, all of
which were up-regulated in HCC compared to adjacent tissues.
The role of the three up-regulated genes in HCC remains to be
studied. Recently, Yeligar et al. [43] showed that miR199 was
inducible by ethanol and that its down-regulation may contribute
to augmented HIF-1alpha and ET-1 expression. Taking together,
RNA-seq analysis revealed that malignant transformation of
hepatocytes might involve the perturbation of multiple important
cellular pathways including cell growth-related pathways, metab-
olism-related processes, immune-related and micro-RNA regulat-
ed pathways.
Accumulated somatic genetic alteration is a hallmark of cancer
genome and a variety of chromosome aberrations have been
identified in HCC tissues through traditional CGH and array-
CGH methods with limited resolutions [2]. Microarray-based
expression profiling data were also intended to use for the
screening of genetic aberrations at the level of chromosome [44].
Several published array CGH data and comparative genomic
microarray analysis (CGMA) have identified the amplification of
chromosomal 8q, 1q, 20q, 17q and the deletion of chromosome
4q, 8p, 13q, 16q, 17p as frequently events in HCC [32,33,45]. In
the present study, we for first time attempted to make full use of
RNA-seq data for the screening of chromosomal aberrations in
HCC. Our data indicated that many of chromosomal aberrations
predicted in our study were almost identical to what was
previously reported [2], such as the amplification of 8q24. The
chromosome region of 8q24 harbors a number of potential onco-
genes, including c-Myc [46], CCNE2 [47], and RIPK2 [48].
Another chromosomal segment 1q22 was found to be enriched
by many genes that were up-regulated in HCC compared with
adjacent tissues. Wong et al. [49] identified that this segment was
amplified in HCC tissues. In contrast, chromosomal regions 4q12,
4q23 and 4q32 were enriched by genes that were down-regulated
in HCC when compared with adjacent tissues. These regions were
loci with loss of heterozygosity (LOH) in HCC [44]. These results
suggested that the deep sequencing might be feasible and reliable
for screening of chromosome aberrations with higher resolution
and sensitivity. Except for the findings as previously reported, we
also predicted several novel potential chromosome aberrations,
which were not found in previous array-based studies. Among
them, a representative chromosome regions were located on the
chromosome 15.1, which were enriched by a number of up-
regulated carcinogenesis-related genes, such as OIP5, a potential
cancer therapeutic target [50], and PAK6, a member of the p21-
activated kinase (PAK) family of serine/threonine kinases, may
play roles in the regulation of cell motility and in stress responses
[51]. Our findings gave a deep insight into the HCC pathogenesis
at the level of chromosome. Further studies are still needed for the
detailed explanation of chromosome aberrations in hepatocarcin-
ogenesis.
Alternative splicing is a process in which cells can selectively
include different regions of pre-mRNA during RNA processing
and it was found to be implicated in carcinogenesis [52]. However,
the complex nature of alternative splicing makes its discovery not
easy. Previous efforts using exon arrays have achieved only limited
success [53]. Taking advantage of the RNA-seq technology, we
were able to analyze differential expression at the exon levels,
providing a way to understand fine scale regulation of gene
expression at alternative transcript level for the same gene. We first
characterized in detail three patterns of regulation and confirmed
the existence of all these three patterns (Fig. 6). Made possible due
to the power of the RNA-seq technology, our database provides
the most comprehensive characterization of relationship between
gene regulation at gene and exon levels. It will become an
important resource for the scientific community to understand the
complex molecular mechanism of hepatocarcinogenesis.
Our data set also allows us to identify novel splicing events (Fig. 7)
that are not previously annotated or reported even by the huge EST
sequencing efforts. For example, we identified a novel splicing
variant for ATAD2 (ATPase family, AAA domain containing 2) that
was over expressed in HCC samples. ATAD2 is a very important
molecule as it is a cofactor for MYC, AR (androgen receptor) and
ERalpha and the gene itself is regulated by both estrogens and
androgens [54,55]. ATAD2 maps to chromosome 8q24, a region
that is frequently found to be amplifiedincancers includinginHCC
as we described above. It has 28 exons and the splicing events would
create a transcript lacking exon 6–8 and result in a protein isoform
that misses 136 amino acids from the original ATAD2 protein. A
functional domain search using the InterPro scan program (http://
www.ebi.ac.uk/Tools/pfa/iprscan/) revealed that the skipping
region matches to the pfam domainPF05764 (YL1 nuclear protein),
which has DNA-binding properties. However, the ATP binding
domain(ataminoacidposition467–474)ofthe ATAD2proteinwas
not affected by this exon skipping event. In addition, we found that
this skipping region contains a trinucleotide repeat that translates
into a peptide sequence characterized by 24 aspartic acids (D) and
15 glutamic acids (E), both of which are negatively charged amino
acids (Fig. 7D). To date, the biological significance of skipping this
repeat sequence and the functional of the novel ATAD2 isoform
remains to be determined, and further investigation is warranted.
A limitation of our dataset in analyzing splicing events is that we
only used 36-nucleotide sequence reads for the alignment. In the
analysis pipeline, only tags with more than 8 nucleotides (nt)
spanning each of the two joining exons were considered as
evidence for a putative splicing event. Although this approach
could be highly sensitive, it also results in high false positive rate.
Future work using longer sequencing reads or using paired-end
sequencing will help to alleviate the problem.
In conclusion, this study for the first time utilized next
generation sequencing platform to comprehensively characterize
the HBV-related HCC transcriptome. The full characteriztion of
the landscapes of the HCC transctiptome provides the basis for an
understanding of the molecular mechanisms of HCC pathogenesis
at system-wide levels. Future research works based on our findings
may speed up the discovery of novel biomarkers and drug targets
for improving diagnosis and therapy of HCC.
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